Latest Gynecologic Oncology Group Stories
Women's Oncology Research & Dialogue has lanched a new website to inform women about ovarian, uterine, cervical and all gynecologic cancers at wordoncancer.org. Indianapolis, IN (PRWEB) November 9, 2010 On November 9, 2010 Women's Oncology Research & Dialogue launched their new website at http://www.wordoncancer.org. WORD was founded with the mission of spreading awareness as well as offering insight and education on gynecologic cancers to the world. Founded by two gynecologic...
TORONTO, Sept. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study has been approved and will be sponsored by the Cancer Therapy Evaluation Program, Division of Cancer...
IRVINE, Calif., Aug. 4 /PRNewswire/ -- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, is pleased to announce their partnership with The Gynecologic Oncology Group (GOG) through the Industry Collaboration Team (ICT) program. By becoming a member of the ICT, OvaGene Oncology demonstrates its commitment to building a strong partnership with the GOG research groups, namely...
IRVINE, Calif., July 12 /PRNewswire/ -- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today that it has completed license agreements with key Norwegian cancer researchers. The agreements allow OvaGene to validate two new promising genomic technologies with the intention of developing these into clinical laboratory tests. Validation studies and the subsequent...
PITTSBURGH, June 30 /PRNewswire/ -- Precision Therapeutics, a life-science company known for their expertise in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, continues to gain ground in novel genomic testing and bioinformatics research. Precision Therapeutics has recently recruited key scientific research experts, biostatisticians and medical specialists to support their development efforts. "I think Precision is addressing...
IRVINE, Calif., June 22 /PRNewswire/ -- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today the opening of its new clinical and research laboratory in Irvine, California. This state-of-the-art facility will serve as the central headquarters for operations, research, and molecular clinical lab testing. The opening of the laboratory is an important first step for...
New Survey Offers Data Updates into Practice Patterns, Compensation and Demographics of Gynecologic Oncologists and the State of Women's Cancer Care CHICAGO, June 22 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO), the country's leading organization of board certified women's cancer specialists, is now offering the results of its member-based, demographic and practice survey: "Gynecologic Oncology 2010: State of the Subspecialty." The comprehensive survey takes an...
HACKENSACK, N.J., June 7 /PRNewswire/ -- The John Theurer Cancer Center at Hackensack University Medical Center announced today the addition of Ami Vaidya, M.D. to the division of gynecologic oncology. Dr. Vaidya is dual-board certified in gynecologic-oncology and obstetrics-gynecology. She brings a world-class education and more than seven years of gynecology experience to the cancer center. "We are thrilled to have Dr. Vaidya join our expert gynecologic oncology team," said Andrew L....
Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.The international, multi-center, randomized, double-blind,...
Updated Survey Data Offers Insights into Practice Patterns, Compensation and Demographics of Gynecologic Oncologists and the State of Women's Cancer Care CHICAGO, May 18 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO), the country's leading organization of board certified women's cancer specialists, has just released the results of a member-based, demographic and practice survey: "Gynecologic Oncology 2010: State of the Subspecialty." The comprehensive survey takes...
